Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Inventory (2016 - 2026)

Collegium Pharmaceutical has reported Inventory over the past 10 years, most recently at $40.9 million for Q4 2025.

  • For Q4 2025, Inventory rose 15.05% year-over-year to $40.9 million; the TTM value through Dec 2025 reached $40.9 million, up 15.05%, while the annual FY2025 figure was $40.9 million, 15.05% up from the prior year.
  • Inventory for Q4 2025 was $40.9 million at Collegium Pharmaceutical, up from $38.1 million in the prior quarter.
  • Over five years, Inventory peaked at $80.1 million in Q1 2022 and troughed at $15.5 million in Q1 2021.
  • A 5-year average of $37.6 million and a median of $34.8 million in 2023 define the central range for Inventory.
  • Biggest five-year swings in Inventory: skyrocketed 417.14% in 2022 and later tumbled 66.53% in 2023.
  • Year by year, Inventory stood at $17.4 million in 2021, then skyrocketed by 167.34% to $46.5 million in 2022, then crashed by 30.47% to $32.3 million in 2023, then grew by 9.98% to $35.6 million in 2024, then grew by 15.05% to $40.9 million in 2025.
  • Business Quant data shows Inventory for COLL at $40.9 million in Q4 2025, $38.1 million in Q3 2025, and $38.1 million in Q2 2025.